Videos

Addressing the importance of safe treatments for PTSD, Dr John Miller discusses adverse effect management practices and the role of REMS protocols.

Focusing on the future of PTSD treatment, Dr John Miller outlines how novel treatments can address current challenges and unmet needs in the therapeutic landscape.

John J. Miller, MD, provides an overview of the symptom clusters of PTSD and treatments that are being looked at to improve patient care.

The Psychiatric Times editor-in-chief shares perspectives on how a novel treatment, MDMA-assisted therapy, can potentially change the treatment landscape and improve patients’ lives.

John J. Miller, MD, discusses how the diagnosis and treatment of posttraumatic stress disorder (PTSD) has evolved over time.

Karl Doghramji, MD, FAASM, DFAPA, and Chelsie Monroe, MSN, APN, PMHNP-BC, conclude the discussion with advice for clinicians who treat patients with narcolepsy.

Experts on narcolepsy offer perspectives on non-pharmacologic interventions for pediatric patients with narcolepsy, including lifestyle changes.

Focusing on the case of a 9-year-old with excessive daytime sleepiness and sudden episodes of muscle weakness, the panel discusses the difficulty in diagnosing pediatric patients with narcolepsy.

Building upon the discussion of a complex case of a patient with narcolepsy, the panel provides clinical insights on cotreatment practices.

Chelsie Monroe, MSN, APN, PMHNP-BC, and Karl Doghramji, MD, FAASM, DFAPA, discuss the complex case of a 23-year-old man who presents with excessive daytime sleepiness, cataplexy, hallucinations, and episodes of neurocardiogenic syncope.

The panel offers comprehensive insights on adapting narcolepsy treatments for patients who experience adverse effects, achieve partial response, or have a history of substance abuse.

Experts on narcolepsy discuss review the case of a 35-year-old woman with excessive daytime sleepiness and hypnagogic hallucinations and offer their clinical insights on treatment strategies.

Focusing on the evaluation and management of narcolepsy, experts provide insights on clinical assessment practices and treatment classes.

Chelsie Monroe, MSN, APN, PMHNP-BC, and Karl Doghramji, MD, FAASM, DFAPA, offer comprehensive insights on how to diagnose narcolepsy, highlighting symptoms and diagnostic testing practices.

Richard Jackson, MD, and Micheal Asbach, DMSc, PA-C, provide their key takeaways from these studies and insights on how providers can assess the impact of of tardive dyskinesia (TD) in every visit.

Richard Jackson, MD, and Micheal Asbach, DMSc, PA-C, discuss the physical, psychological, and social impacts of of tardive dyskinesia (TD) and how it may affect a patient’s underlying conditions.

Richard Jackson, MD, and Micheal Asbach, DMSc, PA-C, discuss the impact of of tardive dyskinesia (TD) on a caregiver’s life and work, highlighting the need for clinicians to support all allies in their patient’s support network.

Richard Jackson, MD, and Micheal Asbach, DMSc, PA-C, provide an overview of tardive dyskinesia (TD) and highlight recent studies that assessed the burden of TD on patients.

John M. Kane, MD, and Erin Crown, PA-C, CAQ-Psychiatry, provide closing thoughts on improving schizophrenia care in the future, highlighting the importance of personalizing treatment, shared decision-making, treatment recommendations, and keeping patients engaged.

Experts on narcolepsy delve into the pathophysiology of the disorder, reviewing its underlying mechanisms and emphasizing the pivotal role of orexins in regulating sleep.

Karl Doghramji, MD, FAASM, DFAPA, and Chelsie Monroe, MSN, APN, PMHNP-BC, utilize their expertise in the management of sleep disorders to provide an overview of narcolepsy, educating the audience on how to recognize this condition in their patient populations.

A comprehensive discussion on new treatment options for patients with schizophrenia, highlighting the potential for earlier intervention to optimize treatment outcomes.

Erin Crown, PA-C, CAQ-Psychiatry, and John M. Kane, MD, discuss awareness among physicians of the concept of cognitive impairment associated with schizophrenia and detail unmet needs, including the lack of approved therapies, measurement tools, and access to cognitive remediation.

Two experts in the management of schizophrenia provide further insights on the disease pathophysiology, highlight the inflammatory impact on dendritic spines, and explore treatment considerations for this condition.

Erin Crown, PA-C, CAQ-Psychiatry, and John M. Kane, MD, provide clinical insights on the treatment of the three symptom domains of schizophrenia, highlighting their manifestations and treatments, including iclepertin.

John M. Kane, MD, and Erin Crown, PA-C, CAQ-Psychiatry, introduce themselves and provide an overview of schizophrenia, highlighting the burden, stigma, prevalence, and the three symptom domains.

"It was word and note, The wind the wind had meant to be—A little through the lips and throat. The aim was song—the wind could see."

"But where are the songs of praise for church basements? That lower level, that rock bottom room sunken & reverent with flickering lights..."

Have you seen "Dune: Part Two?" H. Steven Moffic, MD, gives his social psychiatric review.